Showing posts with label Avista Capital Partners. Show all posts
Showing posts with label Avista Capital Partners. Show all posts

Saturday, April 6, 2019

Avista Capital Partners Acquires Dermatology Business Unit


Since 2005, Thompson Dean has served as cofounding CEO of Avista Capital Partners, a New York City-based private equity firm focused on investments in growth-oriented health care companies. Some of Thompson Dean and Avista's recent business activities include acquiring the extended topicals and dermatology unit of G&W Laboratories. 

Headquartered in South Plainfield, New Jersey, G&W Laboratories leverages more than 100 years of experience to provide people with a variety of high-quality products. The company's portfolio consists of approximately three dozen topical dermatology products, such as creams, ointments, liquids, and gels.

In partnering with G&W Dermatology, Avista named Walt Kaczmarek, a business executive with over 25 years of pharmaceutical industry experience, to serve as CEO. He is working with G&W's established team to oversee existing and pipeline products as well as the company's research and development and manufacturing capabilities. 

Avista's acquisition of G&W Dermatology does not affect G&W Laboratories' other business activities, including manufacturing operations in Pennsylvania and North Carolina. The Avista portfolio currently comprises over $6 billion of investments in approximately 30 health-oriented businesses.

Friday, April 27, 2018

Avista Capital Partners Completes Sale of Zest Dental Solutions


As the CEO of Avista Capital Partners, Thompson Dean draws on experience gained in leadership positions at Goldman Sachs and DLJ Merchant Banking Partners. At Avista, Thompson Dean and his partners employ a middle-market control buyout strategy of creating value through management enhancements, regulatory understanding, and greater financing options.

Since its inception more than a decade ago, Avista Capital Partners has focused on investing in companies in the health care sector with substantial potential for added value. One of these companies is Zest Dental Solutions, a Carlsbad, California-based company in which Avista invested in 2013. During its partnership with Avista, Zest emerged as one of the premier international providers of innovative dental restoration products and full-arch treatment solutions.

In February 2018, Avista Capital Partners announced that it would sell Zest to funds controlled by the private-equity firm BC Partners for undisclosed terms. Avista was represented in the transaction by the global legal firm Ropes & Gray, which was led by a team that included finance partner Sunil Savkar, private equity partners David Blittner and Bob Rivollier, tax partner Leo Arnaboldi, and benefits partner Alexandra Alperovich.

Saturday, February 3, 2018

Avista Capital Partners Acquires Growth-Focused United BioSource


Based in New York, New York, Thompson Dean leads Avista Capital Partners as co-founder and chief executive officer. In this role, Thompson Dean pursues transformative acquisition strategies that include growth-focused buyouts. In November 2017, Avista reached an agreement with Express Scripts Holding Company for the acquisition of its wholly-owned subsidiary United BioSource (UBC).

In business for 15 years, UBC has maintained a leading presence in patient support and pharmaceutical services, with an emphasis on making medical products and drugs more accessible and safe. With 13 locations across North America and Europe, the Pennsylvania-based firm excels in generating and evaluating real-world evidence that informs the life cycles of medical products.

Executives with both companies described the acquisition as an ideal partnership that will help the firms thrive in a dynamic and expanding industry, all while improving patient care. The companies’ combined health care sector expertise sets them on a path to enable more biopharmaceutical companies to accelerate therapy approvals, in the process expanding access to essential medications and therapies.